We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

A Q&A with Lorenzo Galluzzi

The Editor-in-Chief of OncoImmunology

INTERESTED IN CONTRIBUTING AN ARTICLE?
Lorenzo Galluzzi - Editor-in-Chief of OncoImmunology

Meet the Editor

Lorenzo Galluzzi (born 1980) is currently Assistant Professor of Cell Biology in Radiation Oncology with the Department of Radiation Oncology of the Weill Cornell Medical College (New York, NY, USA), Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine (New Haven, CT, USA), Honorary Associate Professor with the Faculty of Medicine of the University of Paris (Paris, France), and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara (Ferrara, Italy), the Graduate School of Pharmacological Sciences of the University of Padova (Padova, Italy), and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza” (Rome, Italy).

He is also Associate Director of the European Academy for Tumor Immunology (EATI), and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP).

OncoImmunology

Q1 Rank   |   2020 Impact Factor 8.110   |   2020 CiteScore 11.5

What is OncoImmunology journal about?

OncoImmunology publishes top-quality, innovative research dissecting the complex, bidirectional interactions between cancer cells and the host immune system. OncoImmunology considers not only papers dealing with fundamental, mechanistic questions, but also translational work aimed at generating knowledge that can be actioned in the clinic, as well as purely clinical research testing novel immunotherapeutic regimens or identifying prognostic or predictive biomarkers that are validated prospectively.

The journal aims at growing to an ever more prominent position amongst the journals currently dealing with cancer immunology as a unique discipline at the interface between oncology and classical immunology.

As the longstanding Editor of OncoImmunology, what are your plans for the next year?

OncoImmunology is a rapidly expanding journal that currently receives more than 1000 submissions per year. Our goal remains to treat each of such submissions at unparalleled speed, with triage times <48h and average time to comments from reviewers <3 weeks, in full consideration of the time pressure that most research groups experience.

What research topics would you like to see more of in the journal this year?

Most definitely research attempting to elucidate and potentially circumvent immunological mechanisms of resistance to conventional chemotherapeutics, radiotherapy and targeted anticancer agents that were not conceived as immunotherapies. I strongly believe we have been harnessing the patient’s immune system in our fight against cancer for much longer that we intended to, and elucidating the immune pathways driven by conventional therapies may rapidly pave new avenues to combinatorial regimens with superior clinical activity.

As a prospective author, what are the benefits of publishing open access in OncoImmunology?

There are several aspects that matter when it comes to scientific publishing, one of which is the dissemination of results. Publishing open access ensures that the efforts of years of investigation become readily available to each and every member of the community as soon as the paper goes live on the Oncoimmunology website, which is crucial for rapid scientific development in (and potentially outside of) the field.

How can someone who would like to publish in OncoImmunology go about doing so?

The authors of original papers can directly proceed to submission by clicking on “Submit an article” button in the OncoImmunology website, and one of the Editors will be in touch shortly after submission about general suitability of the paper for external peer review. Conversely, prospective authors of review articles and commentary should first get in touch with me to make sure there is an interest in moving forward on the specific topic of discussion, knowing that these contributions are generally solicited by the EiC of the journal.

What support can you give researchers hoping to publish in your journal?

I am available and happy to provide my take on potential submissions to OncoImmunology informally, in the form of pre-submission inquiries that can be made by e-mail or over the phone. This may not only be limited to identifying prospective articles that matches the novelty, quality and priority scores that are required for publication in OncoImmunology, but may also include suggesting additional experiments that may be required for consideration and/or commenting on how to best present research results in view of external peer reviewing.

Feeling inspired?

If you're feeling inspired to publish your research in OncoImmunology, click on the options below to find out more. 

AIMS & SCOPE INSTRUCTIONS FOR AUTHORS SUBMIT NOW

Keep up to date with the latest research by following us on Twitter @tandfmedicine